Surrozen, Inc./DE (SRZN) stock
SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$30.67−1.07 (-3.37%)
Close on Nov 19, 2026Market cap $360.48MP/E –Yield –
Surrozen shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Surrozen's shares outstanding was 23M at Jun 30, 2026. For fiscal 2025 it was 0M, up 155.0% from the year before. The highest annual figure on record is 1M in fiscal 2020.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0M | +155.0% |
| FY2024 | Dec 31, 2024 | 0M | +45.3% |
| FY2023 | Dec 31, 2023 | 0M | -12.8% |
| FY2022 | Dec 31, 2022 | 0M | +40.6% |
| FY2021 | Dec 31, 2021 | 0M | -99.8% |
| FY2020 | Dec 31, 2020 | 1M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 23M | +171.0% |
| Q1 FY2026 | Mar 31, 2026 | 0M | +201.8% |
| Q4 FY2025 | Dec 31, 2025 | 0M | +180.2% |
| Q3 FY2025 | Sep 30, 2025 | 0M | +165.5% |
| Q2 FY2025 | Jun 30, 2025 | 9M | +320.1% |
| Q1 FY2025 | Mar 31, 2025 | 0M | -99.8% |
| Q4 FY2024 | Dec 31, 2024 | 0M | +62.9% |
| Q3 FY2024 | Sep 30, 2024 | 0M | +41.8% |
| Q3 FY2023 | Sep 30, 2023 | 2M | -12.8% |
| Q2 FY2023 | Jun 30, 2023 | 2M | -14.0% |
| Q1 FY2023 | Mar 31, 2023 | 0M | -99.9% |
| Q4 FY2022 | Dec 31, 2022 | 0M | -99.9% |
| Q3 FY2022 | Sep 30, 2022 | 2M | +92.0% |
| Q2 FY2022 | Jun 30, 2022 | 2M | +192434.5% |
| Q1 FY2022 | Mar 31, 2022 | 2M | +92.6% |
| Q3 FY2021 | Sep 30, 2021 | 2M | +48.1% |
| Q2 FY2021 | Jun 30, 2021 | 1M | – |
| Q1 FY2021 | Mar 31, 2021 | 0M | – |
| Q4 FY2020 | Dec 31, 2020 | 1M | – |
| Q3 FY2020 | Sep 30, 2020 | 1M | – |
See a number that looks wrong?